The BNF for Children is the unrivalled guidance on prescribing, dispensing and administering medicines to children.
BNF for Children is the only child-focused drug formulary in the world that is both independent, and has rigorous, accredited content creation processes. It is trusted by health professionals worldwide as their primary source for minimising medication errors in paediatrics.
Sales and UpgradesContent Updates
Speed and safety: Provides rapid reference to essential information on the selection of safe and effective medicines for individual patients
Evidence Grading: As part of NICE accreditation recommendations, BNFc content is now evidence graded to reflect the strength of evidence behind them, increasing transparency to support healthcare professionals with clinical decision making
Always up-to-date: The content is revalidated, revised, and updated on a monthly basis, making sure you access only the very latest prescribing knowledge
Worldwide credibility: The BNFc uses clinical evidence from a diverse range of sources and a network of experts, giving you the confidence to select medicines safely
*based on average data in the last 12 months
This update contains 3 significant changes, 4 dose changes, 1 new monograph and 5 new preparations.
Significant Changes:
• COVID-19 vaccines: updated guidance for immunisation.
• Methylphenidate hydrochloride long-acting (modified-release) preparations: caution if switching between products due to differences in formulations [MHRA/CHM advice].
• Nebulised asthma rescue therapy in children: home use of nebulisers in paediatric asthma should be initiated and managed only by specialists [MHRA/CHM advice] (advice in ipratropium bromide, salbutamol, terbutaline sulfate; see example in ipratropium bromide).
Dose Changes:
• Prednisolone [update to dosing for infantile spasms].
• Tetracosactide [update to dosing for infantile spasms].
• Vigabatrin [update to dosing for infantile spasms].
• Xeljanz® (tofacitinib) [update to dosing for polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis using oral solution].
New Monograph:
• Sibnayal® [potassium citrate with potassium bicarbonate].
New Preparations: Avenor®, Seffalair Spiromax®, Sereflo Ciphaler®, Stalpex® [fluticasone with salmeterol]; Nuvaxovid® [COVID-19 vaccine].
For further details on changes in the BNFC click on https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes
This update contains 5 significant changes, 3 dose changes, and 1 new preparation.
Significant Changes:
• Antibacterials, use for prophylaxis: updated guidance for the prevention of secondary cases of diphtheria.
• Diphtheria vaccine: updated guidance for immunisation.
• Influenza vaccine: updated guidance for immunisation.
• Urinary-tract infections: updated guidance for management of lower urinary-tract infection and pyelonephritis, acute.
• Valaciclovir [update to indication and doses in line with UK Health Security Agency recommendations on post-exposure prophylaxis for chickenpox and shingles].
Dose changes:
• Aciclovir [update to indication and doses in line with UK Health Security Agency recommendations on post-exposure prophylaxis for chickenpox and shingles].
• Colecalciferol [update to dosing for primary prevention and treatment of Vitamin D deficiency].
• Ergocalciferol [update to dosing for primary prevention and treatment of Vitamin D deficiency].
New preparations:
• WockAIR® [budesonide with formoterol].
For further details on changes in the BNFC click on
https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes
This update contains 7 significant changes, 3 dose changes, 5 new monographs, 1 new preparation, and 1 deleted preparation.
Significant Changes:
• Cystic fibrosis transmembrane conductance regulator modulators: update to hepatic impairment advice (see example in ivacaftor).
• Epilepsy: updated guidance on management.
• Hydrocortisone: addition of children’s dosing for adrenal crisis.
• Immunisation schedule: updated guidance for immunisation against influenza.
• Influenza vaccine: updated guidance for immunisation.
• Tezacaftor with ivacaftor and elexacaftor: name change to ivacaftor with tezacaftor and elexacaftor.
• Topiramate (Topamax®): start of safety review triggered by a study reporting an increased risk of neurodevelopmental disabilities in children with prenatal exposure [MHRA/CHM advice].
Dose Changes:
• Briviact® (brivaracetam) [update to age range].
• Ivacaftor with tezacaftor and elexacaftor [update to age range].
• Tezacaftor with ivacaftor [update to age range].
New Monographs:
• Aklief® [trifarotene].
• Magnesium citrate.
• NovoThirteen® [factor XIII A-subunit (recombinant)].
• Palforzia® [peanut protein].
• Zepatier® [elbasvir with grazoprevir].
New Preparation:
• Assicco® [glycopyrronium bromide].
Deleted Preparation:
• Codeine phosphate solution for injection.
For further details on changes in the BNFC click on https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes
This update contains 2 significant changes, 1 dose change, 2 new monographs and 1 new preparation.
Significant Changes:
• Metformin hydrochloride: reduced vitamin B12 levels and new advice for monitoring patients at risk [MHRA/CHM advice].
• Type 1 diabetes: inclusion of continuous glucose monitoring in aims of treatment.
Dose Changes:
• Cyanocobalamin [update to indications and dose].
New Monographs:
• Bylvay® [odevixibat].
• Colchicine.
New Preparations: Uxil® [dasatinib].
For further details on changes in the BNFC click on https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes
This update contains 3 significant changes, 2 new monographs, and 1 new preparation.
Significant Changes:
• Anagrelide: risk of thrombosis, including cerebral infarction, if treatment discontinued abruptly [MHRA/CHM advice].
• Denosumab (Prolia®): should not be used in patients under 18 years due to the risk of serious hypercalcaemia [MHRA/CHM advice].
• Tacrolimus: updated pregnancy, breast-feeding and monitoring advice.
New Monographs:
• Aubagio® [teriflunomide].
• Ngenla® [somatrogon].
New Preparations:
• Ogluo® [glucagon].
For further details on changes in the BNFC click on
https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes
This update contains 6 significant changes, 3 dose changes, and 2 new monographs.
Significant Changes:
• Ear: updated guidance for the management of acute otitis media.
• Human papillomavirus vaccine: updated guidance in-line with UK Health Security Agency recommendations.
• Immunisation schedule: updated guidance for immunisation against human papillomavirus and influenza.
• Influenza vaccine: updated guidance in-line with UK Health Security Agency recommendations.
• Paediatric Steroid Treatment Card to support early recognition and treatment of adrenal crisis in children with adrenal insufficiency [British Society for Paediatric Endocrinology and Diabetes] (advice in alclometasone dipropionate; beclometasone dipropionate; benzyl benzoate with bismuth oxide, bismuth subgallate, hydrocortisone acetate, peru balsam and zinc oxide; betamethasone; budesonide; ciclesonide; cinchocaine hydrochloride with fluocortolone caproate and fluocortolone pivalate; cinchocaine with hydrocortisone; cinchocaine with prednisolone; ciprofloxacin with fluocinolone acetonide; clobetasol propionate; clobetasone butyrate; deflazacort; dexamethasone; diflucortolone valerate; fludrocortisone acetate; fludroxycortide; flumetasone pivalate with clioquinol; fluocinolone acetonide; fluocinonide; fluorometholone; fluticasone; gentamicin with hydrocortisone; hydrocortisone; hydrocortisone butyrate; hydrocortisone with lidocaine; loteprednol etabonate; methylprednisolone; mometasone furoate; prednisolone; triamcinolone acetonide; triamcinolone hexacetonide; see example in dexamethasone).
• Pain, chronic: new guidance for management in children.
Dose Changes:
• Dexamethasone [update to dosing for COVID-19 requiring supplemental oxygen].
• Erythromycin [amended age range for otitis media and sore throat in children].
• Human papillomavirus vaccines [update to indications and dosing].
New Monographs:
• Givlaari® [givosiran].
• Rinvoq® [upadacitinib].
For further details on changes in the BNFC click on https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes
